Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycophorin A and Band 3 are the two most abundant integral membrane proteins of human erythrocytes. Band 3 (SLC4A1/AE1) is a major anion transporter responsible for chloride/bicarbonate exchange critical to CO₂ transport in the blood, and also contributes to membrane structural stability by interacting with the red cell cytoskeleton. Glycophorin A (GPA) is a heavily glycosylated protein that contributes to the erythrocyte surface glycocalyx and prevents red cell aggregation. GPA is essential for efficient band 3 maturation and cell-surface expression, and together with Band 3, defines several clinically significant blood group antigens (notably, the Wright antigen). Defects or polymorphisms in either can result in hemolytic diseases, altered blood group phenotypes, and influence susceptibility to certain infections including malaria[2][3][1][4].
Inhibitors (e.g., DIDS, SITS) block chloride/bicarbonate exchange by binding to Band 3 conferring anti-transport effects Antibodies targeting GPA or Band 3 (transfusion medicine, experimental therapeutics): induce cell lysis, block parasite entry, or tag cells for destruction
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycophorin A and Band 3 (GPA and AE1).